journal article·2025-09Open access

Crystal structure of quizartinib hydrate, C 29 H 32 N 6 O 4 S•(H 2 O) 1/3

James A. Kaduk, Anja Dosen, Tom N. Blanton

Powder Diffraction· Volume 40· Issue 3

Abstract

Abstract The crystal structure of quizartinib hydrate has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Quizartinib hydrate crystallizes in space group P-1 (#2) with a = 13.9133(9), b = 17.877(3), c = 19.8459(30) Å, α = 115.080(5), β = 93.768(5), γ = 100.831(5)°, V = 4,332.1(6) Å 3 , and Z = 6 at 298 K. In the complex crystal structure, the molecules are generally oriented parallel to the (110) plane. Two of the independent molecules are linked into dimers by N–H···O or N–H···N hydrogen bonds. Each molecule exhibits a unique pattern of C–H···O, C–H···N, or C–H···S hydrogen bonds. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File ™ (PDF ® ).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Thermal and Kinetic Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Illinois Institute of Technology

North Central College

The International Centre for Diffraction Data (ICDD)

Funding

International Centre for Diffraction Data

References (32)

Show source-provided references
1. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
2. 2023
3. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
4. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
5. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
6. 10.1017/S088571562400015010.1017/S0885715624000150 ↗
7. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
8. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
9. 2013
10. 10.1063/1.46788210.1063/1.467882 ↗
11. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
12. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
13. 10.1016/j.chphi.2022.10014710.1016/j.chphi.2022.100147 ↗
14. 10.1021/ci049780b10.1021/ci049780b ↗
15. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
16. 10.1107/S010876810000723010.1107/S0108768100007230 ↗
17. 2024b
18. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
19. 2023
20. Bravais · 1866
21. 10.1002/anie.19951555110.1002/anie.199515551 ↗
22. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
23. 10.1002/jcc.2315310.1002/jcc.23153 ↗
24. 2023
25. 10.1107/S160057752100249610.1107/S1600577521002496 ↗
26. 2024a
27. A New Law of Crystal Morphology Extending the Law of Bravais
28. 10.1007/BF0054909610.1007/BF00549096 ↗
29. Bhagwat, S. S. , Lai, W. , Parent, S. D. , Roe, M. J. , Schwartz, A. , and Smolenskaya, V. N. . 2014. “Solid Forms Comprising N-(5-tert-butyl-isoxazol-3-yl)-N’-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-B][1,3]benzothiazol-2-yl]phenyl]urea, Compositions Thereof, and Uses Therewith.” U.S. Patent 8883783B2.
30. 10.1021/ar00172a00510.1021/ar00172a005 ↗
31. 10.1017/S088571561400090610.1017/S0885715614000906 ↗
32. 10.1107/S160057671901409210.1107/S1600576719014092 ↗